In vivo gene therapy viruses (HGF, etc.)
Hepatic diseases, Diabetes mellitus
PreclinicalPipeline development
Key Facts
Indication
Hepatic diseases, Diabetes mellitus
Phase
Preclinical
Status
Pipeline development
Company
About Surv Biopharma
A Kagoshima University spin-out developing survivin-promoter-driven oncolytic viruses and gene therapy vectors for oncology and metabolic diseases.
View full company profile